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Abstract
KAYLEE GRACE HOLMES: A Study of the Antioxidant Versus Pro-oxidant Nature of
the Amyloid Beta Peptide and an Analysis of the Natural Products, Isorhamnetin and
Naringenin, as Antioxidants
(Under the direction of Dr. Saumen Chakraborty)
Alzheimer’s disease is a neurodegenerative disorder with no cure. Due to the
widespread effects of this disease, abundant research efforts have gone towards finding a
cure. The amyloid beta (Ab) peptide has been shown to be a potential cause of the disease
due to destructive effects on tissues that it can have both by itself and through reactive
oxygen species (ROS) generation. This study was performed in order to assess the
structural properties of Ab42 monomers, fibrils and oligomers, to assess the antioxidant
versus pro-oxidant behavior of the Ab peptide, and to assess the antioxidant nature of the
natural products isorhamnetin and naringenin. Several different ROS assays were
performed in order to gain insight into the nature of Ab42, isorhamnetin, and naringenin. It
was found that the oligomeric form of the peptide behaved solely as a pro-oxidant and
generated much more ROS than the monomers and fibrils. The monomers and fibrils,
however, showed antioxidant behavior as they decreased the amount of ROS generated by
free copper under oxidative conditions. Isorhamnetin was far more successful at reducing
ROS generation in all forms of the peptide than naringenin. After performing a copper
titration, it was determined that two isorhamnetin molecules are able to bind one copper.
These results indicate that Ab42 oligomers behave as pro-oxidants while Ab42 monomers
and fibrils behave as antioxidants. The results also indicate that isorhamnetin is a better
antioxidant than naringenin.
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Chapter 1: Introduction

1.1 Alzheimer’s Disease
Worldwide, the leading cause of dementia is Alzheimer’s Disease as 50-80% of all
dementia cases are due to Alzheimer’s.1 According to the World Health Organization, there
is approximately 18 million cases of Alzheimer’s worldwide.1 Its development has been
found mostly in people over the age of 60, yet approximately 5% of all cases occur in
people under the age of 60.1 The Alzheimer’s disease is a fatal neurodegenerative disease
meaning there is loss of structure and function of the nerve cells that will eventually lead
to death.2 The type of nerve cells specifically affected in Alzheimer’s are those of the
cerebral cortex.2 Due to the fact that there is no known cure for Alzheimer’s Disease, it is
not surprising that there is considerable research going towards finding a cure.1
The greatest risk factor in Alzheimer’s Disease is increased age, and with humans
progressively living longer, Alzheimer’s Disease is becoming more and more prevalent.1
In the next 20 years, the cases of the AD are expected to double, and by the year 2050,
there is expected to be around 125 million cases of Alzheimer’s disease.1,3 With increasing
AD cases expected to develop each year, there is also significant cost associated with the
disease. According to the Alzheimer’s Association and the National Institute on Aging, in
the United States AD costs about $100 billion dollars annually (both direct and indirect
costs included).3 However, the invention of new treatments that could delay the onset of
AD for even just five years would save the US and approximately $50 billion dollars
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annually.3 Taking into account the fatality of the disease as well as its estimated progression
and financial burden, it is clear to see why finding a cure for the disease is a priority in the
world of research.

1.2 The Role of Amyloid Beta in Alzheimer’s Disease
In Alzheimer’s Disease, there are two distinct pathologies that are found in the brain;
extracellular plaque deposits of the amyloid-b peptide and the neurofibrillary tangles of the
micro-tubule binding protein tau.4,5 Although the tau protein does appear to be involved in
the progression of AD, it is processed downstream of the amyloid-b peptide buildup.6,9
Amyloid-b has two species: one consisting of 40 amino acids and the other consisting of
42 amino acids.5 The Ab42 form is believed to be more neurotoxic.8 Amyloid-b is generated
by the cleavage of the transmembrane amyloid precursor protein (APP), where its Nterminus originates from the extracellular domain of APP and the C-terminus originating
from the transmembrane region of APP.5 When mutation occurs in APP, there is either an
increased production of amyloid-b or an increased proportion of the amyloid-b-42 residue.5
Many of the mutations in APP have little effect on its functionality but instead cause the
tendency of amyloid-b to form fibrils.7 Hereditary early onset forms of AD are linked to
mutations within the amyloid-b precursor protein (AbPP), although these cases make up
only about 1% of the total cases of AD.1,4 APP undergoes substantial post-translational
processing which can be in form of glycosylation, phosphorylation, and many other forms
including various types of proteolytic processing to generate peptide fragments.53 It is most
commonly cleaved by proteases in the secretase family including alpha, beta, and gamma
secretases. The alpha and beta secretases work to remove almost the entire extracellular
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domain in order to release membrane-anchored carboxy-terminal fragments while the
gamma secretases cleave within the membrane spanning domain.54,55 The cleavage of beta
secretases followed by the cleavage of gamma secretases leads to the generation of the
amyloid peptide.55 The cleavage of APP to form the amyloid-beta peptide is shown below
in Figure 1.

Figure 1. This figure illustrates the cleavage of APP to form the Ab peptide. Here, the a, b, and g secretases
work to cleave APP from the membrane as well as to further cleave it into the Ab peptide. The Ab peptide
is represented by the yellow rectangle and the blue rectangle as well as the black line represent the cleaved
portions of APP. This process occurs during post-translational processing of APP.

In searching for the causative agent of AD, Hardy and colleagues published the
amyloid cascade theory in which they proposed that the deposition of the amyloid-b
peptide was the causative agent of AD.9,10 With this hypothesis they also proposed that the
neurofibrillary tangles of the tau protein, cell death, vascular destruction, and dementia
followed as direct effects of the deposition of the amyloid-b peptide.10 A study was also
done in which mice were given the human gene for increased levels of Ab42 and it was
found that they exhibited molecular, cellular and behavioral phenotypes similar to those
found in AD.11 However, there remain many substantial controversies with this theory.
The most recurring controversy is the fact that amyloid-b deposits have been found in the
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brains of humans who did not report or have symptoms of mental derange.6 This
controversy has been disputed by the fact that the deposits found in many of these subjects
are of the diffuse type, meaning they do not have fibrillar amyloid, neuritic dystrophy or
cytotoxiciticty.6 Controversy has also been disputed by the fact that the soluble amyloid-b
oligomers have not been quantified, and yet the peptide in the soluble oligomeric form is
what is associated with the progression of AD.6 Also, the subjects who were said to not
have had signs of dementia (yet still had amyloid plaques), were not studied thoroughly
enough to be confident whether or not they showed any signs of cognitive impairment.6 In
fact, it has been observed in seemingly normal subjects with amyloid deposits through
amyloid-b imaging by positron emission tomography (PET), that there are often some
cognitive deficiencies in such subjects.6 Lastly, most chronic diseases show significant
amounts of pathology prior to the diseases earliest symptoms.6 With this being true,
amyloid-b deposits in the brain cannot be dismissed for being linked to a cascade of
neurodegeneration characteristic of AD.
Amyloid-b is a metalloprotein with several metal coordination residues and a
hydrophobic core. These attributes along with its sequence are depicted below in Figure
2. Amyloid-b peptide consists in three different structural forms: the monomeric form, the
fibrillar form and the oligomeric form. Though the oligomeric form is thought to be the
most toxic form, it is hard to fully distinguish due to its heterogeneous and metastable
characteristics.10 Originally, amyloid-b was thought to only be toxic in its fibrillar form,
but when fibril formation was inhibited, neurotoxin formation still occurred.11 The
neurotoxin that was found was composed of small diffusible amyloid-b oligomers.11
Because there are other molecules that appear in increased levels in AD affected brains,
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there is a hypothesis that these molecules act as a chaperone to allow Ab to self-associate,
causing diffusible oligomers to form which are more harmful than even the fibrillary form
of the amyloid peptide.11 It was found that small amounts of a senile plaque protein slowly
produced neurotoxin deposits in the central nervous system (CNS). These deposits were
made of amyloid-b oligomers which were small, soluble, extremely diffusible, and toxic
even in dilute nanomolar concentrations to mature CNS neurons.11 This evidence is
remarkable since one of the initial oppositions to amyloid-b being the causative agent for
AD was the fact that it took tremendous amounts of the fibrillary form (initially believed
to be the most toxic form) to kill neuronal cells.12 Since the discovery that Ab oligomers
were indeed the most toxic form of the Ab peptide, extreme efforts have been made in
order to try and better understand the complex oligomeric form of Ab on molecular and
cellular levels.

Figure 2. This figure shows the sequence for the Ab42 peptide. The amino acids highlighted in red indicate
the metal coordinated residues and the amino acids highlighted in blue indicate the hydrophobic core of the
peptide.

1.3 Amyloid Beta Oligomers: their pathway and toxicity
The amyloid peptide is intrinsically disordered meaning it does not have stable
secondary or tertiary structures.10 It can, however, still become folded or partially folded
in particular conditions.13 These conditions include conformational variations, pH,
temperature, concentration of peptide and other external factors.10,13 Due to the fact that
the oligomeric form of amyloid-b is composed of a heterogenous mixture of intermediates
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derived from several different pathways, the characterization of the oligomeric form has
been extremely difficult and complex.10 In addition, the longer Ab residue (Ab42)
introduces even greater variability (than the other major residue, Ab40) in its monomeric
and fibrillary forms.15 Atomic Force Microscope (AFM) images showing the different
morphological features between Ab fibrils and oligomers are shown below in Figure 3.
A

B

Figure 3. This figure shows AFM images taken of the A) oligomeric and B) fibrillar forms of the Ab peptide.
Source: Mitra, Suchitra, Pallavi Prasad, and Saumen Chakraborty. "A Unified View of Assessing the Prooxidant versus Antioxidant Nature of Amyloid Beta Conformers." ChemBioChem 19.22 (2018): 2360-2371.

Before Ab can self-aggregate at all, it first must be cleaved from APP via b- and gsecretases. When Ab monomers become partially folded, they tend to interact with one
another.13,15 This interaction allows their self-recognition sites to come in contact with each
other and this promotes the beginning of self-aggregation.13,15 This process is actually
spontaneous because the interactions between these partially folded monomers are strong
enough to overcome the original desire for disorder in the system.

10,13

Next, oligomeric

species begin to form. Initially, small, toxic oligomers develop and begin to generate a
nucleus.10 The diverse, three-dimensional, Ab species found in the nucleation process are
referred to as on-pathway oligomers. These oligomers are later converted into larger
aggregates or fibrillary Ab units.13,15 However, deviation from this pathway can occur, and
the creation of this deviant species of oligomers are referred to as off-pathway oligomers.
This deviation has been demonstrated by using polyphenol (-)-epigallocatechin gallate

6

(EGCG) in which EGCG was used to redirect the amyloid pathway and thus eliminate the
possibility that amyloid fibrils would form.16 Off-pathway oligomers are non-toxic and are
stable final products unlike on-pathway oligomers which are an intermediary species for
fibril formation during elongation.16 This multistep process is shown below in Figure 4.

Figure 4. This figure illustrates Ab production and aggregation. (A) Ab production occurs due to the
cleavage of APP by b- and g-secretases. Natively the Ab peptide is unfolded, but due to both
environmental and genetic factors, they can become partially folded. (B) During on-pathway
oligomerization, Ab forms structured, transient oligomers which are suspected to be toxic. Off- pathway
oligomers also form and are stabilized without further fibril growth. (C) Structured oligomers are
metastable intermediates that further transform into protofibrils or fibrils. (D and E) Some fibrils can
fragment and reassemble into structured oligomers (fragmentation). In addition, structured oligomers
can be generated through interactions between monomers and fibrils (secondary nucleation).10
Source: Lee, Shin Jung C., et al. "Towards an understanding of amyloid-β oligomers: characterization,
toxicity mechanisms, and inhibitors." Chemical Society Reviews 46.2 (2017): 310-323.

When Ab monomers interact and aggregation occurs, as described previously, the
process is called primary nucleation. However, Ab monomers can instead interact with Ab
fibrils created downstream; this process is referred to as secondary nucleation.17 The
nucleation phase is the rate-determining step during amyloid fibrillation, with secondary
nucleation being significantly faster than primary nucleation. When enough fibrils have
formed to consistently interact with Ab monomers, secondary nucleation becomes the
dominant pathway for amyloid fibrillization.17 In secondary nucleation, monomer-fibril
interactions may cause the process of oligomer formation to be catalyzed.17 Fibrils formed
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through either pathway can dissociate into oligomers under certain stimulus such as force.17
This is referred to as fibril fragmentation.10 A study performed in 2013, suggested there is
a positive feedback loop involving secondary nucleation and fibril fragmentation.17 In the
study, as the oligomeric reservoir grew greater (via fibril fragmentation), secondary
nucleation was promoted, thereby further increasing the oligomeric reservoir at a faster and
faster rate.17 Therefore, oligomer formation can be produced through primary nucleation,
secondary nucleation, and fibril fragmentation, and thus the oligomeric reservoir is
continually increasing which means the toxicity levels also rapidly increase. This rapid rise
in toxicity expedites the neurodegeneration in AD, and thus causes increased concern to
learn how these oligomeric species can be suppressed.
Because it becoming more and more obvious that soluble, diffusible Ab oligomers
exhibit neurotoxicity in AD, the mechanisms by which they become toxic has become
widely studied. There are three major mechanisms in which Ab induces toxicity:
interaction with membranes and synaptic receptors, intracellular system influence, and
cell-to-cell transmission.10 Extracellular amyloid-b oligomers can affect the cellular
membrane in various ways. They can bind the membrane and in doing so cause damaging
changes to the membrane. They can bind to signal transducing membrane receptors, thus
either causing the cell to endocytose them, or generate damage due to abnormal signaling.
They can cause the flow of substances into and out of the cell to be disrupted by penetrating
the cell with circular structures that they form. In vivo and in vitro studies have shown that
there is an interaction between Ab oligomers and lipid rafts (membrane domains consisting
of cholesterol, GM1-ganglioside sphingolipids, and synaptic receptors.)18 In a study
performed on Tg2576 transgenic mice, it was found that although the lipid rafts only make
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up a small portion of total brain volume, they do contain 27% of Ab42 that is found in the
brain and 24% of Ab40 that is found in the brain.18 Because lipid rafts are involved in signal
transduction, the accumulation of Ab oligomers on lipid rafts could hinder signal
transduction causing memory deficits.10 This theory was supported by the Tg2576
transgenic mice study where the accumulation of Ab on lipid rafts in 6 month on mice
caused memory decline.18 Other studies suggest that when Ab interacts with membrane
receptors, that synapse loss is initiated which is believed to be the link between
neurodegeneration and cognitive impairment.19 This interaction also promotes the
endocytosis of oligomers, thus triggering further damage to the intracellular systems. 20 As
previously mentioned, Ab can also be generated and accumulated within the cell. This
accumulation can cause many processes within the cell to have problems. Accumulation
could cause stress to the endoplasmic reticulum (ER), calcium ion imbalance,
mitochondrial damage, altered proteolysis, and ultimately these damages can cause cell
death.21 The final mechanism in which Ab oligomers become toxic is through cell-to-cell
transmission. The mechanism by which Ab oligomers spread is very similar to the way
that prion diseases spread.14 A recent study was conducted in which autopsies of patients
who had received cadaver-derived growth hormone, showed both the prion disease
Creutzfeldt–Jakob disease (CJD), and amyloid-b plaque deposits. These patients had no
genetic mutations linked with hereditary AD. The question arose as to whether or not Ab
pathology could be transmitted in humans similar to the way prion diseases are by way of
seeding.14,22 In a study performed on transgenic mice, concentrations of brain samples from
AD patients were injected into the hippocampal formation or neocortex of the mice.22 After
a few days of incubation, there was no detectable trace of Ab. However, after 3 to 5 months
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post injection, Ab deposits appeared and increased drastically the longer they were allowed
to incubate.22 The degree to which Ab-seeding appeared in the mice was directly
proportional to the concentrations of the brain samples that were injected into the mice.22
The mice that had received brain extracts from non-AD infected brains showed no
significant amounts of Ab deposits.22 The seeding mechanism that is believed to occur
here is through a system of donor and acceptor neurons. The donor already contains the
Ab and the acceptor receives Ab from the donor.10,22 In a study performed by Nath and
colleagues, Ab was fluorescently labeled and was seen to be transferred from donor to
acceptor cells. Ab42 showed the highest transmission rate out of the various isoforms of
Ab.22 This cell-to-cell transmission produced large lysosomal vesicles that had the
potential to dysregulate both the donor and acceptor cells. This is one pathway in which
Ab is believed to spread within the brain of AD patients.14,22 However, more studies need
to be performed to truly gain a complete view of Ab transmission.

1.4 The Role of Metals and Reactive Oxygen Species in Alzheimer’s Disease
The neurodegeneration that takes place in AD is also greatly impacted by the fact that
Ab is a metalloprotein, meaning that Ab is metal-binding.8 Metals are necessary for
enzymatic function and often work to catalyze reactions, provide structural stability, and
they play an important role in cellular signaling.24 Therefore having a healthy balance of
metals like iron, zinc, and copper, is an essential part of a healthy system.24 However, in
diseased brains, these concentrations become much higher than what is considered
healthy.8 Metal dyshomeostasis and abnormalities in the way metals are metabolized are
thought to be directly involved with neurodegeneration in AD.25 The amount of copper that
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is deposited in the brain increases with age, but in AD patients this amount increases to
concentrations as high as ~0.4 mM in the cerebral amyloid deposits.8,23 In healthy cells,
proteins tightly regulate copper, and no free copper is available because of this.8 However,
in diseased cells copper becomes unregulated, and hypermetalation occurs in copper
proteins and Ab peptides.8 In Ab, Cu2+ is believed to bind to His6, His13/His14, the
terminal amine, an O atom (probably a part of the Ala2 backbone) and O-Asp1.8,25 Under
aerobic conditions and in the presence of biological reductants (such as ascorbic acid which
is found at 0.2–10 mM concentrations in the brain), Cu2+ is reduced to Cu+.8 By way of the
Fenton–Haber–Weiss reaction (shown in Scheme 1), this reduction in copper gives rise to
reactive oxygen species (ROS), which include O2-, H2O2 and OH•. Although copper bound
Ab is not the only source for copper reduction, it is the major source and thus accounts for
the majority of ROS production.8,23 This increase in free radical production leads way to
an imbalance between the radicals and antioxidants in the body and thus causes oxidative
stress.26 The proposed structure for the copper-Ab complex is shown in Scheme 1.27
Copper redox cycling is proposed to occur via a preorganized electron transfer (POET)
mechanism.28 This mechanism preorganizes the distances and angles within the Ab-Cu
coordination sphere so that it minimally rearranges upon electron transfer thus lowering
the reorganization energy by 0.3 eV.28 The POET mechanism leads to greater efficiency in
redox cycling. The ROS created thorough this cycling oxidize cellular DNA, RNA,
proteins and lipids, and therefore damage cellular function.30 Lipid peroxidation occurs
when ROS steal electrons from lipids, and this peroxidation produces 4-hydroxynonenal
(HNE) which causes cellular damage specifically with cellular signaling.8,29
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A)

B)

Scheme 1. (A) Proposed Cu2+/Cu+ coordination of Ab; (B) ROS generation by the Fenton-Haber-Weiss
reaction.

Many studies have been performed to try and better understand Cu-catalyzed ROS
production. It is still unclear whether Ab plays an antioxidant role31, a pro-oxidant role32,
or if it can be both an antioxidant and pro-oxidant within Cu-catalyzed ROS production.33
The reasoning behind the antioxidant role of Ab is due to the fact that in solution, the level
of free radicals generated by Ab is lower than the amount of free Cu2+.8 The reasoning
behind the pro-oxidant role of Ab is the fact that the Ab-Cu complex generated more free
radicals than other copper binding peptides.8 Recent studies have shown that both the
monomeric and fibrillar forms of Ab can act as radical scavengers decreasing the amount
of free radicals in vitro.34 It has also been shown that Ab40 fibrils cause redox silencing,
further deceasing the amount of free radicals.35 Though information about the roles of the
monomeric and fibrillar forms of Ab has been studied and better understood, not much is
understood about the role of the oligomeric form. Because the oligomeric form is
considered the most neurotoxic form, it is important to further understand what role the
oligomeric form plays in Cu-catalyzed ROS production.
12

1.5 The Role of Natural Products in Alzheimer’s Disease Research
Many studies have suggested that there are dietary factors involved with the occurrence
of AD, and in response, much research effort has gone towards understanding the influence
that natural products have on Ab toxicity. Specifically natural products with antioxidant
properties and the ability to modulate small molecules are being researched as possible
targets for AD.36 These natural products can chelate metals and regulate metal homeostasis,
alleviate oxidative stress, interact with Ab both covalently and noncovalently, and redirect
the Ab aggregation pathway thus lowering the toxicity of potential aggregates.37
Flavonoids are a family of natural substances containing phenolic structures which are
commonly found in fruits, vegetables, grains, bark, roots, stems, flowers, tea and wine.44
Flavonoids are known for their health benefits specifically in regards to their anti-oxidative,
anti-inflammatory, anti-mutagenic and anti-carcinogenic properties as well as their ability
to regulate cellular enzymatic function.44 In plants, flavonoids play a role in growth and
defense against the formation of plaques which has made them very interesting in regards
to AD research.44 Flavonoids also have been shown to chelate iron and copper ions and
therefore have been studied in regards to their potential relationship with metal-overload
diseases as well as in situations regarding oxidative stress.45 In a study performed by
Holland and colleagues, it was concluded that higher dietary intake of flavanols may
correspond to a decreased risk of developing dementia or Alzheimer’s Disease.47
In this experiment, the natural flavonoids isorhamnetin and naringenin were selected
in order to evaluate their ability to inhibit Cu-Ab42-induced ROS generation and regulation
of the morphology of the monomeric, oligomeric and fibrillar species of the peptide under
oxidative stress. Isorhamnetin (structure shown below in Figure 5A) is an O-methylated
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flavanol. This flavonoid is commonly isolated from water dropwort (Oenanthe javanica,
Umbelliferae).46 Pears, olive oil, wine, tomato sauce, and Mexican tarragon are also
sources of isorhamnetin.47,48 It has been shown to have antioxidant, anti-inflammatory, and
anti-proliferative effects.46 Naringenin (structure shown in Figure 5B) is a flavanone
commonly found in a variation of fruits and herbs and it is the major flavanone found in
grapefruit.49,50 This flavanone exists in two forms: the aglycol form (naringenin) and the
glycosidic form (naringin), with the aglycol form being the most bioavailable.51 Naringenin
has been shown to have antioxidant effects as it decreases oxidative stress in cells.52
B)
A)
C

C
A

B

A

B

Figure 5. (A) Structure for isorhamnetin; (B) Structure for naringenin.

Studies have been performed on a similar flavonoid, kaempferol (shown below in
Figure 6), in which kaempferol decreased ROS production in all species of Ab.8 The study
also demonstrated that two kaempferol molecules bind one Cu2+.8 The study accredited
kaempferol’s antioxidant abilities to three structural features: 1)its para-hydroxy group on
its C-ring provides stability to aryloxy radicals through H bonding and takes part in electron
dislocation, 2) its 2,3-double bond and 4-oxo group on its B-ring contribute to electron
dislocation, 3) its 3- and 5-hydroxy groups that stabilize electron density from the C-ring.8
We predicted that isorhamnetin and naringenin would behave in a similar way due to their
similar structures. Isorhamnetin is structurally the same as kaempferol except for its added
14

methoxy group, and naringenin structurally the same as kaempferol except it is missing a
hydroxy group on its B-ring.

C
A

B

Figure 6. Structure for kaempferol.
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Chapter 2: Methods

2.1 Synthesis and Purification of the Amyloid-b-42 Peptide
Synthesis
In this experiment, Ab42 (NH3+–Ab42-CONH2) was synthesized using an automated
microwave peptide synthesizer (Liberty Blue, CEM). This was done on a 0.1 millimolar
scale using Rink Amide Pro-Tide Resin (CEM) with a poly(ethylene glycol) poly styrene
backbone. In this study, the C-terminal amide was used because it tends to increased
biological stability as well as an increased shelf-life. The coupling steps were performed at
90 ºC for 4 minutes. All amino acids (Advanced Chemtech) were weighed in
concentrations of 0.2 M and dissolved in dimethylformamide (DMF; VWR). The activator
base used was 1 M Oxyma (CEM) and the activator used was 0.5 M N,N’diisopropylcarbodiimide (DIC; Advanced Chemtech) in DMF. The deprotection solution
used was 20% piperidine (Advanced Chemtech) in DMF. Starting at His14, residues were
double-coupled to guarantee that all amino acids were present in the synthesized peptide.
Histidine residues were coupled at 50 ºC for 10 minutes to ensure that no racemization
occurred.
Cleavage
In order to cleave the peptides from the resin and side-chain deprotection, the
synthesized product was treated with 92.5% trifluoroacetic acid (TFA; Advanced
Chemtech), 0.25% triisopropylsilane (TIS; Sigma–Aldrich), 0.25% ethane-1,2-dithol
16

(EDT; Sigma–Aldrich), and 0.25% water, in 10 mL volume. The product was treated for 2
hours at room temperature with continuous stirring. After cleavage, the crude peptides were
filtered, and excess TFS was evaporated under a low flow of nitrogen gas. The crude
peptides were then precipitated, washed with cold diethyl ether, dissolved in 10% acetic
acid, and lyophilized. Then, the peptides were dissolved a second time in 10% acetic acid.
After the peptides were dissolved in acetic acid, the peptides were ready for purification
via High Performance Liquid Chromatography (HPLC).
High Performance Liquid Chromatography
Using a C18-semiprep column (1260 Infinity II HPLC system, Agilent), the peptide
was purified. The column compartment was kept at 75 ºC. A linear gradient from Solvent
A (0.1% TFA in H2O) to Solvent B (90% acetonitrile, 10% H2O, 0.1% TFA) was used.
Next, the peptide was injected at 1 mL•min-1 and eluted with 90% A and 10 % B for 5
minutes followed by a linear gradient to 70% B over 25 minutes at a flow rate of 4 mL•min1

. The peptide was eluted at about 50-60% Solvent B. The elution of the peptide was

monitored via a chromatogram at 214 and 280 nm. The purified peptide was then
lyophilized and stored in its monomeric form.

2.2 Preparation of Peptide Stocks
The purified and lyophilized peptide (1mM) was dissolved in 1,1,1,3,3,3hexafluoropropan-2-ol (HFIP). These treated peptides were then placed in Eppendorf tubes
(caps kept open) and left under the hood overnight. Next, the tubes were lyophilized in
order to create films of completely unaggregated peptides. These peptides were kept at -80
ºC and used as needed.
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In order to create a usable monomeric form of the peptide stocks, 100 µL of freshly
made 10 mM NaOH (made from a freshly prepared 1 M NaOH stock) was placed into an
Eppendorf tube containing the lyophilized and purified peptide (dissolved in HFIP). This
tube was then vortexed for 30 seconds. After being vortexed, the tube was sonicated for 10
minutes at room temperature. Finally, the tube was centrifuged at 15000 g And room
temperature for 3 minutes and immediately transferred to ice. The final concentrations of
the monomeric peptides were then determined in cold water with an Agilent 8454 UV/Vis
spectrophotometer by using Beer’s Law (Equation 1) where e280=1490 M-1cm-1. Water
with 10 mM NaOH was used as the blank.

2.3 Preparation of Amyloid-b-42 Fibrillar and Oligomeric Forms
Fibrillar Form
The fibrillar form of the peptide was prepared using premade monomeric peptides
of known concentrations (as discussed in Section 2.3). Ab monomers were mixed with
phosphate buffered saline (PBS; pH 7.4) to achieve a fibril concentration of 100 µM. Once
the PBS was added to the monomer, the tube was then incubated for 24 hours at 37 ºC.
Figure 7B, shown below, depicts this preparation.
Oligomeric Form
The oligomeric form of the peptide was also prepared using premade monomeric
peptides of known concentrations (as discussed in Section 2.3). To achieve a final
concentration of 25 µM, Ab monomers were mixed with PBS (pH 7.4). Next, the mixture
was centrifuged for 30 minutes at 15000 g and room temperature. Once the centrifugation
was complete, the supernatant was taken from the tube and the pellet was disposed of. The
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supernatant was then sonicated for 1 minute at room temperature. Once sonication was
complete, the capped tube was allowed to sit at room temperature for 24 hours before being
used experimentally. Figure 7A, shown below, depicts this preparation.

Figure 7. This figure depicts the methods of preparation of A) oligomers and B) fibrils used in this
experiment.

2.4 Confirmation of Peptide Purity using MALDI-TOF MS
The identity and purity of the synthesized peptide stock was confirmed using
MALDI-TOF MS (Bruker Voyager) with sinapinic acid (Sigma–Aldrich, 10 mg•mL-1
stock in ACN/H2O (50:50) with 0.1% TFA) as the matrix. Using a ProteoMass calibration
kit (Sigma-Aldrich) the instrument was externally calibrated. The sample, which contained
a 1:1 ratio of peptide to matrix, was then loaded onto a MALDI plate and analyzed.

2.5 Preparation of Reagents
All buffer solutions were prepared in Milli-Q (Millipore) water and treated with
Chelex 100 (Bio Rad) overnight to ensure that no trace metals remained in solution. The
following day, the buffer was filtered using a buffer filter. The 1mM copper chloride stock
solution (Alpha Aesar) was made in the presence of 40 mM glycine (Sigma-Aldrich) in
order to prevent the precipitation of copper phosphate in the solution. This copper
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chloride/glycine solution was the source of copper throughout the experiment. The ascorbic
acid 10 mM stock solution (VWR) was prepared fresh daily in water. The 10 mM
coumarin-3-carboxylic acid (3-CCA; Acros Organics) stock solution was prepared in
phosphate buffer (PB; 20 mM; pH 9.0) at room temperature, and then was stored at -20 ºC.
Prior to use, the 3-CCA was diluted with PB, and using either NaOH or H3PO4 the solution
was adjusted to a pH of 7.4. The stock solutions of naringenin and isorhamnetin were
dissolved in DMSO to a 7 mM concentration. The 10 mM Amplex Red stock solution was
prepared in DMSO and stored at -20 ºC. The horseradish peroxidases (HRP) stock solutions
were prepared at 10 Uml-1 in PB (pH 7.4).

2.6 Cu2+ Binding to Isorhamnetin
A Cu2+ binding titration of isorhamnetin was performed using an Agilent Cary 8454
UV-Vis spectrophotometer in a 1 cm path-length quartz cuvette. The solutions consisted
of isorhamnetin (20 µM) in HEPES buffer (pH 7.4) with 1% DMSO added to the solution.
For the blank scan, DMSO was substituted for the natural products in the solution. Cu2+
was added in 0.1 equivalent increments and was allowed to stir for 15 minutes before taking
the measurement. When the UV-Vis spectra ceased to change, the Cu2+ had saturated the
natural product and the titration was complete. Using the UV-Vis spectra, absorbance at an
initial major peak l versus the equivalents of copper added was plotted in order to
determine how many equivalents of copper was necessary to saturate isorhamnetin.
Though the same experiment was intended to be performed for naringenin, lab restrictions
prohibited it from being conducted.
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2.7 UV-Vis ASC Assay
UV-Vis spectroscopy is a widely used analytical method, most often utilized for its
quantitative applications. It is commonly used to determine the concentration of analyte in
solution by utilizing Beer’s Law which is shown below in Equation 1.
A=ebc
Equation 1. This equation represents Beer’s Law where A is equal to the absorbance, e is equal to the molar
extinction coefficient, b is equal to the path length and c is equal to the concentration of the analyte.39

A beam of UV and visible radiation is sent through a cuvette containing the sample.
The sample solution then absorbs the light. How the sample absorbs the light is dependent
on the concentration of the sample as well as the samples ability to absorb certain
wavelengths of light. A detector, on the other side of the cuvette, is able to capture the
amount of light that passes through the sample (this light was not absorbed by the
sample).40 The resulting data given by the UV-Vis spectrometer is the absorbance of light
given at specific wavelengths. In order for UV-Vis spectroscopy to be used to analyze a
sample, the sample must be known to absorb light within the UV or Visible region of the
electromagnetic spectrum. In this region of the spectrum , electrons undergo electronic
transitions. Common compounds that absorb in this region are transition metal ions, highly
conjugated organic compounds, and biological macromolecules.40
In this study the kinetics of ascorbic acid (ASC) oxidation was monitored using an
Agilent Cary 8454 UV-Vis spectrophotometer in a 1 cm path-length quartz cuvette. The
decay of the ASC peak was monitored at 265 nm. The samples contained Ab (5 µM), Cu2+
(4.5 µM), ASC (100 µM), naringenin (90 µM) and isorhamnetin (90µM). Chelated
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phosphate buffer was added to the samples to reach a final volume of 320 µL. The
composition of the samples that were used for analysis are shown below in Table 1.

Contents of the Sample
Sample 1

Ab (monomer, oligomer, or fibril), ASC

Sample 2

Ab (monomer, oligomer, or fibril), Cu2+,
ASC
Ab (monomer, oligomer, or fibril),
naringenin, ASC
Ab (monomer, oligomer, or fibril), Cu2+,
naringenin, ASC
Ab (monomer, oligomer, or fibril),
isorhamnetin, ASC
Ab (monomer, oligomer, or fibril), Cu2+,
isorhamnetin, ASC

Sample 3
Sample 4
Sample 5
Sample 6
Sample 7

Cu2+, ASC

Table 1. This table shows the composition of each of the samples involved in the ASC assay. These samples
were run individually for the monomeric, fibrillar, and oligomeric species of the Ab peptide.

All components of the samples were mixed prior to the addition of ASC to ensure
Cu2+ binding. Each sample (without ASC) was placed into the cuvette and a background
reading was taken. The ASC was then added to the cuvette and mixed via pipette mixing.
Immediately following the addition of ASC, the analysis was started. The UV-Vis
spectrophotometer was set to take a reading once every 60 seconds for a total of 3300
seconds. Each experiment was performed at least three times with different preparations of
each Ab species (monomers, oligomers, and fibrils).
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2.8 Fluorescence Hydroxyl Radical Assay
Fluorescence spectroscopy is a type of electromagnetic spectroscopy that analyzes
the fluorescence given off by a sample. It uses a beam of light, usually ultraviolet, to excite
the electrons in a molecule and the excitation causes them to emit light.41 The molecule is
first excited through the absorption of a photon, from its ground electronic state to a
vibrational state in the molecules excited electronic state.42 When the excited molecule
collides with other molecules, it loses vibrational energy until it reaches the lowest
vibrational state possible within that excited electronic state.42 This process is shown in a
Jablonski diagram.42
In this experiment, the Cu-Ab species was probed to produce OH• by the FentonHaber-Weiss Reaction using a colorimetric CCA-3 assay. The kinetics of the oxidation of
3-CCA to the fluorescent molecule, 7-hydroxycoumarin-3-carboxylic acid (7-OH-CCA) ,
by the hydroxyl radical, OH•, were monitored. This was done using a PTI fluorimeter with
the lexcitation set at 395 nm and the lemission set at 450 nm. These wavelengths are where the
fluorescent molecule, 7-OH-CCA, can be detected. The samples contained Ab peptides (10
µM), Cu2+ (9µM), 3-CCA (100 µM) and ASC (100 µM). Chelated phosphate buffer was
added to the samples to reach a final volume of 320 µL. These assays were performed at a
2:1 Ab/Cu2+ ratio. The natural products (isorhamnetin and naringenin) were not analyzed
in this assay because they were dissolved in DMSO which can scavenge OH• and thus alter
results.43 The composition of the samples that were used for analysis are shown below in
Table 2.

Contents of the Sample
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Sample 1
Sample 2
Sample 3

Ab (monomer, oligomer, or fibril), CCA,
ASC
Ab (monomer, oligomer, or fibril), Cu2+,
CCA, ASC
Cu2+, CCA, ASC

Table 2. This table shows the composition of each of the samples involved in the OH• assay. These samples
were run individually for the monomeric, fibrillar, and oligomeric species of the Ab peptide.

All components of the samples were mixed prior to the addition of ASC.
Each sample (without ASC) was placed into the cuvette and a background emission scan
was taken. The ASC was then added to the cuvette and mixed via pipette mixing.
Immediately following the addition of ASC, the analysis was begun. The fluorimeter was
set to obtain one scan every 60 seconds for 3000 seconds. Each experiment was performed
at least three times with different preparations of each Ab species (monomers, oligomers,
and fibrils).

2.9 UV-Vis H2O2 Assay
An Agilent Cary 8454 UV-Vis spectrophotometer in a 1 cm path-length quartz
cuvette was used to monitor the Cu2+-catalyzed H2O2 formation. In the presence of HRP,
Amplex Red reacts with H2O2 to produce the chemical resorufin, and therefore resorufin
was monitored as a direct measure of the relative amount of H2O2 produced.8 Resorufin
absorbs strongly at 572 nm.8 The samples for the H2O2 assays with peptides consisted of
Ab (5 µM), Cu2+ (4.5 µM), Amplex Red (50 µM), HRP (0.1 UmL-1), ASC (100 µM),
naringenin (90 µM), isorhamnetin (90µM), and 1% DMSO which was added to the samples
in order to ensure that the natural products remained soluble. Chelated phosphate buffer
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was added to the samples to reach a final volume of 320 µL. The composition of the
samples that were used for analysis are shown below in Table 3.

Contents of the Sample
Sample 1
Sample 2
Sample 3

Sample 4

Sample 5

Sample 6
Sample 7

Ab (monomer, oligomer, or fibril),
Amplex Red, HRP, DMSO, ASC
Ab (monomer, oligomer, or fibril), Cu2+,
Amplex Red, HRP, DMSO, ASC
Ab (monomer, oligomer, or fibril),
naringenin, Amplex Red, HRP, DMSO,
ASC
Ab (monomer, oligomer, or fibril), Cu2+,
naringenin, Amplex Red, HRP, DMSO,
ASC
Ab (monomer, oligomer, or fibril),
isorhamnetin, Amplex Red, HRP, DMSO,
ASC
Ab (monomer, oligomer, or fibril), Cu2+,
isorhamnetin, Amplex Red, HRP, DMSO,
ASC
Cu2+, Amplex Red, HRP, DMSO, ASC

Table 3. This table shows the composition of each of the samples involved in the H2O2 assay. These samples
were run individually for the monomeric, fibrillar, and oligomeric species of the Ab peptide.

All components of the samples were mixed prior to the addition of ASC to ensure
Cu2+ binding. Each sample (without ASC) was placed into the cuvette and a background
reading was taken. The ASC was then added to the cuvette and mixed via pipette mixing.
Immediately following the addition of ASC, the analysis was begun. The production of
H2O2 was monitored at 572 nm. The UV-Vis spectrophotometer was set to take a reading
once every 60 seconds for a total of 3300 seconds. Each experiment was performed at least
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three times with different preparations of each Ab species (monomers, oligomers, and
fibrils).
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Chapter 3: Results and Discussion

3.1 Confirmation of Peptide Purity using MALDI-TOF MS
HPLC was performed in order to purify the peptide after synthesis. The HPLC
chromatogram is shown below in Figure 8.
A

B

Figure 8. This figure shows the chromatogram that was generated by HPLC during purification. (A) This
plot was monitored at 280 nm where tyrosine can be observed. Because Ab42 contains tyrosine, it can be
monitored to indicate the presence of Ab42 during HPLC. The peak at approximately 18.5 minutes indicates
the purified peptide. (B) This plot was monitored at 215 nm where the peptide bond can be observed. This
peak also occurred at approximately 18.5 minutes and is therefore where the peptide was collected.

After HPLC purification was complete, MALDI-MS was used to verify that purity
of the peptide. Using MALDI-MS, the spectrum shown in Figure 9 was found for the
purified Ab peptide. A strong peak at 4513 m/z emerged which corresponds to the
molecular weight of the Ab42 peptide which is 4514 Da.38 This spectrum ensures that
following HPLC, that the peptide was purified and ready to be used experimentally.
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Figure 9. MALDI-MS of the purified Ab peptide stock. The strong peak at 4513 m/z corresponds to the
molecular weight of the Ab peptide.

3.2 Cu2+ Binding to Isorhamnetin
The ability of isorhamnetin to chelate Cu2+ and scavenge ROS generated by CuAb species was monitored in this experiment. First, titration was used to monitor this.
Gradual amounts of Cu2+ were added to the isorhamnetin solution and spectra changes
were observed until saturation was reached and no further changes occurred. This spectra
is shown below in Figure 10. Two major peaks at 271 nm and 378 nm and one minor
peak at 321 nm from isorhamnetin decayed and eventually two new major peaks at 252
nm and 319 nm formed as isorhamnetin became saturated with copper. This indicates
that isorhamnetin successfully binds copper.
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Figure 10. UV/Vis spectra of Cu2+ binding titration to a solution containing 10 µM isorhamnetin in 20 mM
HEPES buffer (pH 7.4). The starting isorhamnetin spectrum is shown in blue. Subsequent spectra from Cu2+
binding are shown in less intense red, with the final Cu-isorhamnetin spectrum shown as thick red. The
disappearance and emergence of major peaks are shown as blue and red arrows, respectively. The star is
placed directly above the isosbestic point on the plot which indicates the wavelength at which the absorbance
did not change throughout the course of the experiment.

By plotting the absorbance peak at 378 nm against the equivalents of Cu2+ added,
it was found that 0.5 equivalents of copper binds to 1 equivalent of isorhamnetin (Figure
11). Unfortunately this titration was unable to be repeated due to laboratory restrictions
caused by COVID-19. Ideally, there would be no decrease in slope after the saturation
point at 0.5 equivalents.

Figure 11. This figure shows absorbance at 378 nm (where a major peak decayed) versus the equivalents of
copper added. The sample reaches complete saturation at approximately 0.5 equivalents of copper where the
slope of the line ceases to decrease drastically. Therefore, 0.5 equivalents of copper is needed to bind one
equivalent of isorhamnetin. In other words, 2 isorhamnetin molecules are needed to bind 1 copper.
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Kaempferol, a compound with a similar structure to isorhamnetin is believed to
bind 1 copper with 2 kaempferol molecules. This bond is formed between the two
hydroxyl groups on ring B (shown in Figure 6) on two different kaempferol molecules
(four hydroxyl groups total) to one copper molecule. Because the saturation ratio is the
same for isorhamnetin to copper, Figure 12 proposes a potential way in which
isorhamnetin binds copper.

C
A

B

B

A

C

Figure 12. This figure proposes a way in which 2 equivalents of isorhamnetin could bind 1 equivalent of
copper.

Though isorhamnetin seems like it may work equal to kaempferol as an
antioxidant, isorhamnetin also has a potentially pro-oxidant feature. Due to the addition
of a methoxy group on ring C (as compared to kaempferol), it is believed that this
electron donating group may give electrons to Cu2+ causing Cu+ to be stabilized.
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According to the Fenton-Haber-Weiss reaction (shown in Scheme 1B), Cu+ leads to ROS
generation and therefore this portion of isorhamnetin is believed to also exhibit prooxidant behavior.
Ideally, this titration would have also been performed for naringenin, but due to lab
restrictions caused by COVID-19, this was not possible.

3.3 UV-Vis ASC Assay
In this experiment, ASC oxidation was used as a direct measure of the amount of
ROS produced by different species of the Ab peptide. This was performed using 10 µM
peptide and 9 µM Cu2+ in the presence of tenfold excess of ASC. ASC oxidation was
monitored over the course of 3000 seconds by the decay of an absorbance peak at 265 nm.
The oligomeric form of Ab (Figure 13B) consumed ASC the fastest compared to the
monomeric form, fibrillar form, and free Cu. This indicates that the oligomeric form
generates more ROS in a shorter amount of time.
To test the effect of isorhamnetin and naringenin on ASC oxidation, they were
added with a tenfold excess with respect to Cu2+ to the different species of the Ab peptide.
Naringenin did not show much decrease in the generation of ROS production, instead it
only slightly decreased the ROS production in the monomeric form of the peptide, but not
in any of the other forms. Isorhamnetin moderately decreased the amount of ROS produced
in all species of the Ab peptide as shown by the royal blue line in Figure 13. It reduced
ROS production the most for the fibrillar form of the peptide as seen in Figure 13C.
Compared to a study performed by Chakraborty and colleagues using the natural product
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kaempferol, the natural products isorhamnetin and naringenin are not as effective at
reducing ROS production as kaempferol.8
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as a direct measure of ROS production. (A) Ab monomer, (B) Ab oligomer, (C) Ab fibril.

3.4 Fluorescence Hydroxyl Radical Assay
Using a colorimetric 3-CCA assay, the ability of each Cu-Ab species to produce
OH• by the Fenton-Haber-Weiss reaction was assessed. Consistent with the ASC oxidation
and H2O2 experiments, the oligomeric form of the peptide showed the highest rate of OH•
production compared to the monomeric and fibrillar forms of the peptide. This can be seen
in Figure 14, where the red line in Figure 14B increases more than the red line in Figure
14A (monomer) and Figure 14C (fibril). In all cases the amount of OH• produced by free
Cu2+ (shown by the turquoise line in Figure 14) was much greater than the amount
produced by the Cu-Ab complex. The lower amount of OH• produced by the monomeric
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and fibrillar forms of the peptide suggest that they effectively scavenge OH• , and thus
hinder the production of the fluorescent molecule, 7-OH-CCA. Therefore, these forms of
the peptide appear to behave as antioxidants against radicals. The increased production of
OH• in this study along with the increase in ROS production in both the ASC and H2O2
assays indicates that the oligomeric form acts as a pro-oxidant. The differences in OH•
production between each of the Ab species indicates that there are inherent differences in
the structure of their Cu binding complexes which changes the efficiency of electron
transport and thus the amount of ROS produced also is affected.
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3.5 UV-Vis H2O2 Assay
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The relative amounts and rates of H2O2 production by each Ab species was
monitored in this assay by the detection of resorufin at 572 nm. The data retrieved is
shown below in Figure 15. The oligomeric form of the peptide produced substantial
amounts of H2O2 with the absorbance shown to reach about 1.2. The monomeric form of
the peptide produced less than the oligomeric form of the peptide with its maximum
absorbance shown to reach about 0.8. The fibrillar form of the peptide, generated far less
H2O2 with its maximum absorbance only reaching half of what the oligomeric form did
(about 0.6). The monomeric and oligomeric forms of the Cu-Ab complex showed to
produce more H2O2 than free Cu2+. This was only substantial for the oligomeric form
since about two times the amount of H2O2 was generated for the Cu-AbO complex than
was generated for free Cu2+ in solution. This confirms the pro-oxidant role of the
oligomeric form of the peptide. Though the Cu-AbM complex showed to generate more
H2O2 than free Cu2+ it was not major at all, and thus does not imply a pro-oxidant role of
the monomeric form, and does not negate the antioxidant properties shown in the ASC
oxidation assay. The fibrillar form showed a substantial decrease in H2O2 production
compared to that produced by free Cu2+ in solution, therefore confirming the antioxidant
role of the fibrillar form demonstrated in the ASC oxidation assay.
Isorhamnetin showed a substantial decrease in the amount of H2O2 production in
all forms of the peptide, with in all cases the amount of H2O2 produced being less than
that of even just Ab in solution (without Cu2+). Naringenin, however, showed minimal
decrease in H2O2 production. Overall, in both the ASC oxidation study and in the H2O2
study, isorhamnetin was much better at decreasing ROS production than naringenin.
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Chapter 4: Conclusion
This study was performed in order to assess the structural properties of Ab42
monomers, fibrils and oligomers, to assess the antioxidant versus pro-oxidant behavior of
the Ab peptide, and to assess the antioxidant nature of the natural products isorhamnetin
and naringenin.
First, the synthesis and purification of Ab42 was performed, and then the
purification of the peptide was evaluated using MALDI-MS. After retrieving the purified
peptide, monomers, oligomers, and fibrils were all prepared. Several different assays
were performed using all forms of the peptide as well as in some cases the natural
products naringenin and isorhamnetin.
The first assay performed was an ASC assay performed on a UV-Vis
spectrometer (Figure 13). It was found that the oligomeric form of the peptide generated
more ROS in a shorter amount of time than the other forms, as it to be expected. It was
also found that naringenin did not show a major decrease in the generation of ROS
production. Isorhamnetin, on the other hand, did moderately decrease the amount of ROS
produced in all species of the Ab peptide, with the most decrease occurring in the fibrillar
form.
The second assay performed was fluorescence hydroxyl radical assay. The
purpose of this assay was to determine which form of the peptide behaved most as a prooxidant as well as to verify the antioxidant nature of the monomeric and fibrillar forms of
the peptide. This experiment was successful as it can be seen in Figure 14 that the
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oligomeric form produced considerably more hydroxyl radical than the other two forms
of the peptide.
The final assay that was performed was an H2O2 assay performed on a UV-Vis
spectrometer. This assay monitored the relative amount of H2O2 produced upon the
presence of ASC in the sample. This experiment showed similar results to the ASC assay.
The oligomeric form of the peptide produced considerably more amounts of H2O2 than
the other forms of the peptide. Isorhamnetin showed a major decrease in the amount of
H2O2 production in all forms of the peptide, with in all cases the amount of H2O2
produced being less than that of even just Ab in solution (without Cu2+). Naringenin,
however, showed minimal decrease in H2O2 production.
Overall it was found that isorhamnetin was drastically more effective in
decreasing ROS species than naringenin. This was shown in both the ASC and H2O2
assays. In order to determine the binding capability of isorhamnetin to copper, a copper
binding titration was performed with isorhamnetin and it was found that 1 equivalent of
isorhamnetin binds 0.5 equivalents of copper. In other words, 2 isorhamnetin molecules
were needed to bind one copper molecule. The proposed isorhamnetin-copper complex is
shown in Figure 12.
The results of this study indicate that Ab42 oligomers behave as pro-oxidants
while Ab42 monomers and fibrils behave as antioxidants. The results also indicate that
isorhamnetin is a better antioxidant than naringenin.
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